[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Zurich\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":672},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,101,0,25,[9,45,66,101,127,162,189,209,227,258,284,307,328,358,386,404,425,449,479,503,533,554,585,613,641],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100614825","phase-2-vortioxetine-for-newly-diagnosed-glioblastoma-100614825",false,"NCT07284628","Vortioxetine for Newly Diagnosed Glioblastoma","A Phase II Drug Repurposing Trial of Vortioxetine for the Treatment of Patients With Newly Diagnosed Glioblastoma","ReVoGlio","Inclusion Criteria:\n\n1. Male or female, age ≥18 years\n2. Patients with histologically confirmed newly diagnosed glioblastoma per CNS WHO 2021 classification\n3. O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status known or tissue available for testing\n4. Karnofsky performance status (KPS) ≥ 70%\n5. Intent to treat with standard radiochemotherapy per EANO guidelines (radiotherapy will 60 Gy in 1.8-2 Gy fractions. Concomitant chemotherapy with temozolomide (75 mg\u002Fm2 daily throughout radiotherapy, including at weekends) followed by six cycles of maintenance temozolomide (150-200 mg\u002Fm2, 5 out of 28 days). Short course radiotherapy at 40 Gy is not allowed.\n6. Female patients must be either documented not to be Women of Childbearing Potential (WOCBP) or must have a negative pregnancy test within 14 days of starting treatment. Additionally WOCBP must agree to use, from the screening to 6 months following the last study drug administration, highly effective contraception methods, as defined by the \"Recommendations for contraception and pregnancy testing in clinical trials\" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu\u002Fctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner. WOCBP are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).\n7. Male subjects able to father children must agree to use two acceptable methods of contraception throughout the study and during 6 months following the last study drug administration (e.g., condom with spermicidal gel). Double-barrier contraception is required.\n8. Personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.\n9. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n1\\. Prior treatment for newly diagnosed glioblastoma except surgery. 2. Intent to be treated with tumor-treating fields. 3. Inability to undergo contrast-enhanced MRI. 4. Inadequate bone marrow, renal and hepatic function:\n\n* Absolute neutrophil count (ANC) \\\u003C 1.5 x 10.9\u002FL; platelets \\\u003C 100 x 10.9\u002FL\n* Hemoglobin (Hb) \\\u003C 9.0 g\u002Fdl. Blood marrow values must be measured independently of transfusion.\n* Chronically impaired renal function as indicated by creatinine clearance \\\u003C 50 mL\u002Fmin or serum creatinine \\> 1.5 upper limit of normal (ULN).\n* Inadequate liver function (ALT, AST, ALP ≥ 2.5 x ULN) 9. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.\n\n  10\\. Any contra-indication to vortioxetine. 11. Medically documented history of active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g., risk of doing harm to self or others), or patients with active severe personality disorders.\n\n  12\\. Pregnancy or breast feeding. 13. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.\n\n  14\\. Concurrent malignancies unless the patient has been disease-free without intervention for at least one year.\n\n  15\\. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.","ALL","18 Years",{"count":21,"type":22},78,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","There is a very urgent need to improve on the currently limited treatment options for patients with glioblastoma. Despite extensive knowledge on the molecular pathogenesis of glioblastoma obtained through genomic, transcriptional and proteomic profiling, targeted therapy efforts have not yielded major advances, likely because of interindividual and intraindividual tumor heterogeneity and redundant oncogenic pathway activation.\n\nAccordingly, there is a strong rationale to approach the challenge of glioblastoma from a different angle, e.g., by ex vivo drug sensitivity profiling which is agnostic to the molecular profile of a tumor. This approach that we have termed \"pharmacoscopy\", has previously been explored in liquid cancers and probably led to improved patient outcomes. Using pharmacoscopy, the antidepressant drug, vortioxetine, has been identified as a lead candidate for further exploration in patients with glioblastoma. Vortioxetine also demonstrated synergistic anti-glioma activity in combination with temozolomide or lomustine.\n\nThe ReVoGlio trial aims at demonstrating that vortioxetine, a drug selected based on ex vivo drug profiling (pharmacoscopy), is of benefit for patients with newly diagnosed glioblastoma.",[28],"Glioblastoma",[28,30,31],"Drug repurposing","Vortioxetine","RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2026-06-24",{"date":40,"type":22},"2029-06",{"name":42,"class":43},"University of Zurich","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100563762","phase-2-ex-vivo-drug-response-evaluation-for-next-generation-care-of-brain-metastases-100563762","NCT06620380","Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases","EViDENCE-BM","Inclusion Criteria:\n\n* Patients must be 18 years or older on the day of signing the informed consent, female or male.\n* Patients must have a Karnofsky performance status of 60 or more\n* Patients must have limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.\n* Patients with a tumor with a targetable oncogenic driver mutation should have already been treated with a targeted agent and options must have been exhausted.\n* Patients must have a clinical indication for surgery for probable brain metastasis\n* Patients will be considered eligible for the study only if the diagnosis of brain metastasis has been histologically confirmed on the sample obtained during the surgery performed after signing the informed consent form for the trial.\n* Any type of primary cancer is allowed: breast cancer, lung cancer, melanoma, other cancers. Patients may have several primary cancers.\n* Patients must have adequate bone marrow, renal and hepatic function documented at screening before surgery\n* Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test\n* Patients must have the ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.\n* Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.\n\nExclusion Criteria:\n\n* Patients with rapidly progressive systemic disease\n* Patients with inability to undergo brain MRI evaluation.\n* Patients with progressive parenchymal brain metastases with an indication for requiring whole brain radiotherapy after surgery. Focal brain radiotherapy after surgery is allowed.\n* Judgement by the investigator that the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Intention to become pregnant during the course of the study.\n* Female who are pregnant.\n* Female who are breastfeeding and who do not agree to discontinue nursing prior to the first treatment initiated during the study.\n* Sexually active males and females of childbearing potential who are not willing to use an effective contraceptive method during the study. Male participants who do not agree not to donate sperm.",{"count":53,"type":22},102,[25],"Pharmacoscopy refers to an ex vivo real-time drug sensitivity profiling platform that has been shown to be of value in the treatment of leukemia (Snijder et al. 2017) (Kornauth et al. 2022) and may help to identify novel treatment opportunities for brain tumors as well (Lee et al. 2022). The rationale for pharmacoscopy-based drug sensitivity testing on real-time patient biopsies or surgery material is multiple: measuring drug response and sensitivity directly in real-time patient material, overcomes the problem of limited molecular biomarkers for established targeted therapeutic options and can identify effective drugs even for non-targeted therapies such as chemotherapy. It can also identify hitherto unknown specific vulnerabilities of cancer cells. Furthermore, testing directly on patient material overcomes the limitations of patient-derived cell cultures, organoids, and patient xenografts, as their prolonged culture times risk cellular adaptations and clonal selection that alter drug sensitivity. Pharmacoscopy maintains the tumor cell composition, including bystander cells or tumor microenvironment, and limits cell culture to max 48 hours. Furthermore, pharmacoscopy measures drug responses on a single-cell and on a high-content level, uniquely allowing to measure the drug sensitivity of tumor cells, and allowing to compare it to the drug cytotoxicity on healthy cells from the same patient. This relative readout has previously been shown to be essential for the correct prediction of a clinical response in haematological malignancies (Snijder et al. 2017) (Kornauth et al. 2022).\n\nThe aim of this study is to generate preliminary data regarding superiority of the personalized pharmacoscopy-guided approach compared to a standard non-pharmacoscopy-guided approach, in patients with brain metastases with an indication for surgery, and limited therapeutic systemic options according to the treating physician.",[57,58],"Brain Metastases","Brain Metastases, Adult",{"date":35,"type":36},{"date":61,"type":36},"2025-09-12",{"date":63,"type":22},"2027-06",{"name":42,"class":43},3,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":18,"minAge":19,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":44},"100644284","fasting-exercise-and-diet-to-activate-autophagy-in-depression-100644284","NCT07664540","Fasting, Exercise, and Diet to Activate Autophagy in Depression","Targeting Autophagy in Depression: Fasting, Exercise, Diet","AutoFast","Inclusion Criteria:\n\n* age: 18-40 years\n* BMI: between 18.5 and 24.9 kg\u002Fm2 (SG1\u002F2) or BMI between 25.0 and 39.9 kg\u002Fm2 (SG3\u002F4)\n* ability to understand the study procedure and give consent\n* Written informed consent\n* SG1 women: any fitness level\n* SG2 men: VO2max \\\u003C 45 ml\u002Fkg\u002FKG29,30\n* Available to conduct CPET on menstrual cycle days 1-5 (SG1\u002F3)\n* No infection with HIV or Hepatitis B\u002FC\n\nExclusion Criteria:\n\n* No infectious illness for at least two weeks prior to the test\n* No vitamin supplementation during the week prior to the performance test\n* SG3 and SG4: More than 1 hour moderate exercise per week\n* No use of hormonal contraceptives in the last 6 months before the onset of the study (SG1\u002F3)\n* a clinically diagnosed menstrual disorder (e.g., polycystic ovarian syndrome or amenorrhea) (SG1\u002F3)\n* having given birth within the 12 months before inclusion in the study (SG1\u002F3)\n* pregnancy or breastfeeding (SG1\u002F3)\n* premenstrual dysphoric disorder (PMDD) (SG1\u002F3)\n* history of epileptic seizure\n* history of depression\n* history of manic or psychotic episode\n* existing\u002Fcurrent eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years\n* inability to communicate adequately in speech\n* inability to follow instructions\n* regular use of medication other than thyroxine\n* alcohol consumption as equivalent doses of more than 12 g of pure alcohol per day on average for women and 24 g of pure alcohol per day for men\n* vegan diet\n* daily nicotine consumption\n* currently or history of (regular) consumption of illegal drugs within the last year\n* known diseases of the cardiovascular system\n* arterial hypertension above 160\u002F90 mmHg at rest\n* known pulmonary diseases\n* arthritis and rheumatic diseases and conditions\n* hematologic diseases\n* bronchial asthma\n* surgery less than 4-6 months ago\n* orthopedic or other diseases (e.g. neurological) that preclude maximum load on the bicycle ergometer\n* anemia (\\\u003C12.0 g\u002Fdl for women and \\\u003C14.0 g\u002Fdl for men)",true,"40 Years",{"count":77,"type":22},120,[79],"NA","Depression is a common mental health condition that affects millions of people worldwide and is a leading cause of disability. Although current treatments can be effective, many patients do not fully recover or experience long-term improvement. This study aims to better understand how lifestyle factors such as physical activity and diet-related processes may influence biological mechanisms that could be linked to depression.\n\nThe study focuses on a natural cellular process called autophagy, which helps cells remove damaged components and maintain healthy function. Autophagy is influenced by energy availability in the body and may be affected by behaviors such as physical exercise and caloric restriction. Early evidence suggests that changes in autophagy may also be linked to mood regulation and depression, but this relationship is not yet well understood in humans.\n\nIn this exploratory study, we will investigate how physical activity influences autophagy and related metabolic and molecular processes in healthy adults. We will also examine whether these effects differ between individuals with different body weight and fitness levels, and between women and men.\n\nA total of approximately 120 healthy adults aged 18 to 40 years will participate. Participants will be divided into four groups based on sex and body weight (normal weight or overweight). Each participant will attend study visits at the University Hospital Zurich and perform a standardized cycling exercise test under medical supervision.\n\nDuring the exercise test, participants will perform a graded cycling protocol that gradually increases in intensity until exhaustion. We will collect small blood samples from a vein and from a fingertip at several time points before, during, and after exercise. Saliva samples will also be collected to measure stress-related hormones. Additional measurements include heart rate, breathing parameters, oxygen consumption, and physical performance.\n\nBlood and saliva samples will be analyzed using advanced laboratory techniques to study changes in metabolism, immune signaling, hormones, gene activity, and markers related to autophagy. These analyses will help identify biological pathways that are activated by exercise and may be relevant to brain health and depression.\n\nParticipants will undergo medical screening before inclusion to ensure safety. Individuals with certain medical conditions or factors that could interfere with the study results will not be included. Participation is voluntary, and participants may withdraw at any time without consequences.\n\nThe study involves minimal risks associated with blood sampling and intense physical exercise, which will be performed under close medical supervision. The expected benefit is improved scientific understanding of how lifestyle-related biological processes may be linked to mental health, which could support the development of new preventive or therapeutic strategies for depression in the future.",[82,83],"Depression - Major Depressive Disorder","Overweight (BMI > 25)",[85,86,87,88,89,90,91,92],"autophagy","multi-omics","depression","steroid hormones","autophagy flux","performance testing","metabolomics","proteomics","NOT_YET_RECRUITING","2026-06-17",{"date":38,"type":36},{"date":97,"type":22},"2026-09-11",{"date":99,"type":22},"2029-09-30",{"name":42,"class":43},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":74,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100642879","phase-4-effect-of-supplemental-oxygen-therapy-on-neurocognitive-performance-in-healthy-highlanders-100642879","NCT07651917","Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders","SPIRIT_1","Inclusion Criteria:\n\n* Signed written consent\n* Age \\>18\n* Kyrgyz ethnicity\n* Born, raised and living at approximately 2500 m\n* Native or fluent in Russian language\n\nExclusion Criteria:\n\n* Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others.\n* Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide\n* Heavy smoking of \\>20 cigarettes per day\n* Not able to read or adhere to the study protocol",{"count":109,"type":22},50,[111],"PHASE4","Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).",[114],"Neurocognition",[116,117,118],"Hypoxia","Altitude","Supplemental oxygen therapy","2026-06-10",{"date":121,"type":36},"2026-06-16",{"date":123,"type":22},"2026-06-18",{"date":125,"type":22},"2026-07-31",{"name":42,"class":43},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":144,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100639454","early-detection-of-amyloidosis-in-monoclonal-gammopathy-using-nuclear-medicine-imaging-100639454","NCT07624760","Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging","Early Detection of Light-Chain Amyloidosis in Monoclonal Gammopathy Using 18F-Florbetaben PET\u002FMR: a Prospective, Single-Center, Observational Study","MGUS-PET","Inclusion Criteria:\n\n* Participation in the COSMO-AL study\n* Available biopsy test result\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating women",{"count":109,"type":22},[79],"The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET\u002FMR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET\u002FMR identify systemic amyloid deposits across clinically and histologically defined patient groups?\n\nParticipants will:\n\n* Be screened for eligibility and asked to sign an informed consent form\n* Have their vital signs measured\n* Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET\u002FMR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET\u002FCT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner\n* Be monitored during and after the scan for any side effects or adverse events\n* Complete study participation at the end of the imaging session (single visit, no follow-up required)",[139,140,141,142,143],"Monoclonal Gammopathy","Monoclonal Gammopathy of Undetermined Significance (MGUS)","Multiple Myeloma","AL Amyloidosis","Systemic Amyloidosis",[145,146,147,148,149,150,151,152,153],"MGUS","MGCS","Amyloid PET","PET\u002FMRI","Florbetaben","Early detection","Systemic amyloidosis","Monoclonal gammopathy","AL amyloidosis","2026-05-28",{"date":156,"type":36},"2026-06-03",{"date":158,"type":22},"2026-10",{"date":160,"type":22},"2028-05",{"name":42,"class":43},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100559379","phase-2-personalized-volume-deescalated-elective-nodal-irradiation-in-oropharyngeal-head-and-neck-squamous-cell-carcinoma-100559379","NCT06563362","Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma","Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck","DeEscO","Inclusion Criteria:\n\n* Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.\n* Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.\n* Age ≥ 18 years, no upper age limit.\n* ECOG performance score \\\u003C 3.\n* History\u002Fphysical examination within 30 days prior to study inclusion by head and neck surgeon and\u002For radiation oncologist.\n* FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.\n* Participants need to provide informed consent.\n\nExclusion Criteria:\n\nInclusion Criteria:\n\n* Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.\n* Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.\n* Age ≥ 18 years, no upper age limit.\n* ECOG performance score \\\u003C 3.\n* History\u002Fphysical examination within 30 days prior to study inclusion by head and neck surgeon and\u002For radiation oncologist.\n* FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.\n* Participants need to provide informed consent.\n\nExclusion Criteria:\n\n* Multilevel primary tumors extending unambiguously beyond the oropharynx into the oral cavity, naso- or hypopharynx\n* Distant metastases detected.\n* Previous surgery, chemotherapy or radiotherapy treatment for other head and neck cancers.\n* Previous surgery in head and neck region affecting the cervical lymphatic system. Dissection of singular lymph nodes for diagnostic purposes before treatment start is allowed.\n* Synchronous or previous malignancies. Exceptions are curatively treated basal cell carcinoma or SCC of the skin, or in situ carcinoma of the cervix uteri, low- or intermediate- risk prostate cancer or breast with a progression-free follow-up time of at least 3 years without any remaining disease burden, or other previous malignancy with a progression-free interval of at least 5 years without any remaining active\u002Fprogressive disease burden regardless whether the treatment is completed or ongoing as a maintenance treatment (e.g. androgen deprivation therapy for prostate cancer).\n* Pregnancy or breast feeding\n* Any severe mental or psychic disorder affecting decision making and ability to provide informed consent.",{"count":77,"type":22},[25],"Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity.\n\nThe study investigates the feasibility of this approach as measured by the number of expected out-of-field recurrencies based on the individual patient's state of disease progression and risk factors",[174],"Oropharynx Cancer",[176,177,178,179,180],"head and neck cancer","radiotherapy","elective CTV","clinical target volume","de-escalation",{"date":182,"type":36},"2026-06-01",{"date":184,"type":36},"2025-02-04",{"date":186,"type":22},"2030-02-28",{"name":42,"class":43},6,{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":74,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":44},"100474517","analysis-of-exhaled-breath-from-patients-with-lung-airway-diseases-bigexbress-100474517","NCT05458934","Analysis of Exhaled Breath From Patients With Lung-\u002FAirway Diseases (BigExBrESs)","BigExBrESs","Inclusion Criteria:\n\n* Signed informed consent\n* Age ≥ 18 years at study entry\n\nExclusion Criteria:\n\n* Physical or intellectual impairment precluding informed consent or protocol adherence\n* Known pregnancy",{"count":197,"type":22},5000,"OBSERVATIONAL","Ananlyis of exhaled breath of patients with lung-\u002Fairway diseases to identify and distinguish respiratory diseases, and improve the disease manangament.",[201],"Lung-\u002FAirway Diseases",{"date":203,"type":36},"2026-05-29",{"date":205,"type":36},"2021-05-11",{"date":207,"type":22},"2030-12-31",{"name":42,"class":43},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":74,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":44},"100474292","exhaled-breath-analysis-in-human-subjects-100474292","NCT05456009","Exhaled Breath Analysis in Human Subjects","Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Human Subjects","Inclusion Criteria:\n\n* \\>= 18 years\n* Informed consent\n\nExclusion Criteria:\n\n* specific exclusion criteria for different subgroups",{"count":217,"type":22},1500,"Identification of exhaled breath pattern of human subjects",[220],"Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary Diseases",{"date":203,"type":36},{"date":223,"type":36},"2019-02-19",{"date":225,"type":22},"2030-03-01",{"name":42,"class":43},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":44},"100289902","deep-brain-stimulation-in-patients-with-incomplete-spinal-cord-injury-for-improvement-of-gait-100289902","NCT03053791","Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait","A Phase I\u002FII Open-label Multicenter Trial to Evaluate Safety and Preliminary Efficacy of Unilateral Deep Brain Stimulation of the Mesencephalic Locomotor Region in Patients With Incomplete Spinal Cord Injury","DBS-SCI","Inclusion Criteria:\n\n1. Informed Consent\n2. Participation in two assessment sessions before enrollment (Screening and baseline)\n3. Willingness and ability to comply with the protocol and to attend required study training and visits\n4. Male or female subjects\n5. Age 18-75\n6. Motor incomplete SCI\n7. Level of lesion: T10 and above, based on AIS level, preservation of sacral function\n8. Focal spinal cord disorder caused by either trauma or non-traumatic and non-progressive condition (like hemorrhage, benign tumor)\n9. Minimum 3 months of recovery after SCI\n10. Completed in-patient rehabilitation program\n11. WISCI II, level \\>2 (0-20 items): assistance of one or more persons. Ability to walk at least 10 meters\n12. Stable medical and physical condition.\n13. Adequate care-giver support and access to appropriate medical care in patient's home community\n\nExclusion Criteria:\n\n1. Enrollment of the investigator, his\u002Fher family members, employees and other dependent persons\n2. Limitation of standing and walking function based on accompanying (CNS) disorders\n3. Cardiovascular disorders restricting physical training or peripheral nerve disorders\n4. Implanted technical devices (pacemaker, defibrillator)\n5. History of significant autonomic dysreflexia\n6. Cognitive disorders\u002Fbrain damage\n7. Drug refractory epilepsy\n8. Severe joint contractures disabling or restricting lower limb movements\n9. Haematological disorders with increased risk of bleeding during surgical interventions\n10. Participation in another study with investigational drug within the 30 days preceding and during the present study\n11. Congenital or acquired lower limb abnormalities (affection of joints and bone)\n12. Women who are pregnant or breast feeding or planning a pregnancy during the course of the study\n13. Lack of safe contraception\n14. Inability of the participant to follow the procedures of the study, e.g. due to language problems, psychological problems, dementia etc.\n15. Known or suspected non-compliance, drug or alcohol abuse\n16. Current or prior malignancy","75 Years",{"count":237,"type":22},5,[79],"Spinal cord injuries are anatomically mostly incomplete, showing tissue bridges of the spinal cord at the injury site. Of the 60% functionally incomplete patients, about half face a life in the wheelchair. Besides conventional rehabilitation, no prominsing further treatment options exist. One of the most plastic systems involved in locomotion is the pontomedullary reticulospinal tract, which is the oldest locomotor command system existing in most vertebrates, including primates. Muscle activation patterns for limb movements are programmed in the spinal cord and have to be activated and coordinated through commands from the so called mesencephalic locomotor region (MLR). The MLR consists of nerve cells in the lower mesencephalic tegmentum sending uni- and bilateral signals through the medullary reticulospinal tracts. Classical physiological studies showed that electrical stimulation of the MLR induce locomotion. For the first time this approach was transferred and recently published in a model of induced incomplete spinal cord injury by the Schwab group. Rats severly impaired in motor hindlimb control with only 10-20% spared white matter, recovered with fully functional weight bearing locomotion under MLR deep brain stimulation (DBS). Even rats with only 2-10% spared white matter regained weight supporting stepping. DBS is a clinical standard treatment option in patients with movement disorders but does not relieve all symptoms. Therefore, small studies of MLR stimulations have been safely used in Parkinsonian patients showing freezing of gait and frequent falls with variable results. In a translational approach, we aim at performing a multidisciplinary phase one clinical trial with 5 patients and incomplete spinal cord injury. With the means of our established universitary setup for DBS treatments the operations will be performed unilaterally under local anaesthesia in the Division of Neurosurgery, USZ, with perioperative electrophysiological recordings, clinical assessments and gait analysis under test stimulation in the Spinal Cord Injury Center Balgrist.",[241],"Spinal Cord Injury",[243,244,245,246,247,248,249,250,251],"Deep brain stimulation","DBS","Spinal cord injury","SCI","Paraplegia","Mesencephalic locomotor region","MLR","Pedunculopontine nucleus","PPN",{"date":203,"type":36},{"date":254,"type":36},"2018-03-15",{"date":256,"type":22},"2027-12",{"name":42,"class":43},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":74,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":283},"100557502","direct-measurement-of-ingestive-behaviour-in-relation-to-sex-differences-and-gastrointestinal-hormone-levels-in-patients-after-metabolic-and-bariatric-surgery-100557502","NCT06538948","Direct Measurement of Ingestive Behaviour in Relation to Sex Differences and Gastrointestinal Hormone Levels in Patients After Metabolic and Bariatric Surgery","DIBASH","Inclusion Criteria:\n\n* Age ≥ 18 year\n* BMI ≥ 35 kg\u002Fm2 for patients with planned RYGB or SG operation\n* BMI ≥ 30 kg\u002Fm2 for external controls affected by obesity but no planned RYGB or SG within the next 12 months, and\n* BMI ≥ 18.5 kg\u002Fm2 and ≤ 24.9 kg\u002Fm2 for controls without obesity.\n\nExclusion Criteria:\n\n* history of previous bariatric operations and\u002F or revisional surgery (e.g., alteration of limb lengths after primary RYGB),\n* smoking,\n* established diagnosis of type 1 or 2 diabetes mellitus, and\n* polycystic ovary syndrome (PCOS).",{"count":266,"type":22},420,"Bariatric surgery (BS), especially procedures like Sleeve Gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), is the most effective treatment for obesity. Yet, the exact mechanisms governing its effect are somewhat elusive, with current research mainly focusing on post-operative food intake outcomes based on self-reported data, which might not fully capture the nuanced changes in eating behaviours.\n\nTo address these gaps, our study plans to employ the newly developed \"drinkometer\", a device capable of analysing the intricate changes in drinking behaviour following BS. This tool promises to bring a more detailed perspective to the changes in ingestive behaviours, bypassing the inaccuracies of self-reporting methods. By expanding our research to encompass diverse patient demographics and examining potential links to physiological shifts like gut hormone level alterations, the study aims to provide a more rounded understanding of the long-term impacts of BS on eating behaviours.",[269],"Obesity",[269,271,272,273,274],"Ingestive Behaviour","Bariatric Surgery","Gut Hormones","Drinkometer","2026-05-14",{"date":277,"type":36},"2026-05-18",{"date":279,"type":36},"2024-02-13",{"date":281,"type":22},"2027-12-31",{"name":42,"class":43},2,{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":292,"minAge":19,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":283},"100639087","weekly-online-ct-or-mr-adaptive-definitive-sbrt-for-very-high-risk-localized-or-regionally-metastatic-prostate-cancer-100639087","NCT07591051","Weekly Online CT or MR Adaptive Definitive SBRT for Very High Risk Localized or Regionally Metastatic Prostate Cancer","Weekly Online CT or MR Adaptive Definitive SBRT for Very High Risk Localized or Regionally Metastatic Prostate Cancer (HARP)","HARP","Inclusion criteria include:\n\n* Very high risk localized defined (cN0) according to NCCN guidelines consisting of ≥2 of the following:\n\n  * cT3 disease and\u002For\n  * Gleason 8-10 and\u002For\n  * PSA ≥40 (the baseline PSA value should be doubled for PSAs taken while on 5-alpha reductase inhibitors) OR\n* Regionally metastatic prostate cancer (cN1, any T, any Gleason, any PSA) according to NCCN guidelines consisting of ≤3 lymph node metastases of any of the following:\n\n  * Obturator\n  * Internal iliac (hypogastric)\n  * External iliac nodes\n  * Presacral nodes\n  * Common iliac (below iliac bifurcation)\n  * Periprostatic\u002FPerivesical AND\n* Good to moderate performance status (WHO 0-2)\n* Written informed consent.\n* A PSMA PET and multiparametric MRI is mandatory according to staging guidelines.\n* Age ≥ 18 years\n\nExclusion criteria include:\n\n* ≥4 regional lymph nodes\n* Patients with cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and\u002For pelvic wall)\n* Previous RT to the pelvis or prostate\n* Previous radical prostatectomy\n* Large body size that would not fit into the MRI-simulator bore\n* Presence of distant metastases (i.e. cM1)\n\n  * Non-regional lymph nodes (M1a):\n  * Common iliac\n  * Para-aortic \u002F retroperitoneal\n  * Inguinal\n  * Mediastinal or supraclavicular\n  * Mesorectal\n  * Other\n  * Bone metastases (M1b)\n  * Other sites (M1c)\n* Contraindications to CT or MR-adaptive SBRT (e.g., pacemakers, severe claustrophobia).\n* Severe comorbidities that may interfere with treatment or follow-up (e.g. inflammatory bowel disease)\n* Significant concomitant diseases (e.g. hepatic dysfunction, cardiovascular disease, etc.);\n* Inability to follow procedures or insufficient knowledge of project language, inability to give consent.\n* Participation in a clinical trial, which might influence the results of this project.\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.\n* Severe GU or GI symptoms (e.g., recent urinary retention or diarrhea ≥ grade 3 or obstipation to CTCAE v.5.0).\n* Severe urinary symptoms (prostate volume \\>60mL and\u002For IPSS \\>12)","MALE",{"count":294,"type":22},54,[79],"This interventional prospective multicenter international study will include 54 patients with very high-risk localized (cN0 cM0) or regional (i.e. cN1 cM0) prostate cancer according the NCCN criteria.\n\nPatients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. In the case of regional lymph nodes, a simultaneous integrated boost (SIB) of involved lymph nodes will be performed with 5 x 6.5 Gy. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL with 5 x 9 Gy can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.\n\nThis study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for localized or regional prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality.\n\nWeekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population.\n\nA diagnostic high field MRI during radiotherapy, e.g. week 3 is optional.\n\nFollow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).",[298],"Prostate Cancer","2026-05-12",{"date":301,"type":36},"2026-05-15",{"date":303,"type":22},"2026-05",{"date":305,"type":22},"2033-07",{"name":42,"class":43},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":74,"sex":18,"minAge":19,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":44},"100550146","pain-phenotyping-in-patients-with-neuropathic-pain-after-spinal-cord-injury-100550146","NCT06443281","Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Spinal injury cohort - general inclusion criteria:\n* Aged between 18-80 years\n* Traumatic and non-traumatic etiology\n* Para- and tetraplegic SCI\n* Complete and incomplete SCI\n* SCI with and without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* SCI since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* SCI since more than one year\n* Control cohorts with peripheral neuropathy:\n* General inclusion criteria:\n* Aged between 18-80 years\n* Neurological disorder affecting the peripheral nervous system (i.e., peripheral neuropathy)\n* Peripheral neuropathy with or without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* Peripheral neuropathy since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* Peripheral neuropathy since more than one year\n* Control cohorts without neuropathy \u002F healthy volunteers\n* General inclusion criteria:\n* Aged between 18-80 years\n* No medical condition affecting the peripheral and\u002For central nervous system (e.g., pain, systemic disease, psychological disorder)\n\nExclusion Criteria:\n\n* Inability to follow study instructions\n* Pregnancy\n* Medically manifested psychological disorder\n* Medical condition affecting the peripheral and\u002For central nervous system other than the desired experimental condition (e.g., additional peripheral neuropathy in the SCI cohort)","80 Years",{"count":315,"type":22},300,"The development of neuropathic pain is one of the most debilitating sequels after a spinal cord injury (SCI). The overall aim of this study is to investigate potential underlying pathophysiological mechanisms of neuropathic pain after SCI. The functionality of the nociceptive pathway in humans as well as its plastic changes following SCI will be inferred with sophisticated sensory and pain phenotyping using quantitative sensory testing (i.e., psychophysical measures), objective neurophysiological measures of pain processing and the recording of pain-related autonomic responses (i.e., galvanic skin response, cardiovascular measures and pupil dilation). In addition, the interplay between the somatosensory and autonomic nervous system and its association with the development and maintenance of neuropathic pain after SCI will be investigated.",[318,319,320,321],"Spinal Cord Injuries","Pain, Neuropathic","Nociceptive Pain","Neuropathy",{"date":301,"type":36},{"date":324,"type":36},"2024-04-17",{"date":326,"type":22},"2030-04-30",{"name":42,"class":43},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":335,"minAge":19,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":344,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":44},"100638328","natural-cervical-ripening-to-prevent-pharmacological-induction-of-labor---a-pilot-study-100638328","NCT07587632","Natural Cervical Ripening to Prevent Pharmacological Induction of Labor - a Pilot Study.","Cervinat","Inclusion Criteria:\n\n* Singleton gestation\n* Non-insulin dependent, dietetically managed gestational diabetes\n* Greater than or equal to 34 weeks.\n* Planned vaginal birth at the University Hospital of Zurich\n* Planned IOL for 40 weeks of gestation.\n* Communication in German and\u002For English language possible.\n\nExclusion Criteria:\n\n* Pregnant women with multiple gestation\n* Fetal macrosomia \\>95th percentile\n* Intrauterine growth restriction \\\u003C3rd percentile\n* Already in labor (regular contractions or premature rupture of membranes (PROM)\n* Patients scheduled for IOL before 40 weeks\n* Insulin-dependent diabetes\n* Planned cesarean section\n* Planned birth in an external hospital\n* Inability to follow the procedures e.g. due to language problems, psychological disorders","FEMALE",{"count":337,"type":22},74,[79],"As of today, around 25% of all vaginal births happen after induction of labor (IOL). The internal guidelines of the University Hospital Zurich currently recommend pregnant women with a non-insulin dependent gestational diabetes an IOL around term. One possibility to prevent an IOL and increase the chance for a spontaneous onset of birth is a ripening of the cervix by alternative methods in an outpatient setting. The primary objective of this study is to evaluate the effect of natural cervical ripening methods on the time interval between 37 weeks (beginning of the intervention) and the onset of spontaneous labor.",[341,342,343],"Pregnancy","Induction of Labor","Gestational Diabetes Mellitus (GDM)",[345,346,347,348,349,350],"gestational Diabetes","Induction of labor","cervical ripening","pregnancy","colostrum banking","membrane sweeping","2026-05-07",{"date":275,"type":36},{"date":354,"type":36},"2026-04-10",{"date":356,"type":22},"2029-12-31",{"name":42,"class":43},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":374,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":44},"100414125","emdr-treatment-in-ptsd-following-cardiac-events-100414125","NCT04672551","EMDR Treatment in PTSD Following Cardiac Events","EMDR_PTSD_MI","Inclusion Criteria:\n\n* Age between 18-70 years\n* Men or women\n* STEMI (irrespective of troponin, but ST-elevation) or non-STEMI (troponin positive) at the time of the cardiac event, as verified by the cardiologist\n* Diagnosis of PTSD caused by the cardiac event\n\nExclusion Criteria:\n\n* Psychotic disorder, bipolar disorder, substance abuse as measured with the Mini International Neuropsychiatric Interview (M.I.N.I)\n* Acute suicidal ideation as assessed with the M.I.N.I.\n* Non-selective beta blockers (e.g., propranolol) during the study period\n* Ongoing psychological\u002Fpsychiatric treatment outside of the trial during the study period\n* Visionary problems, e.g. strabismus, which does not allow adequate eye movements\n* Insufficient knowledge of the German language\n* Expected inability or willingness to follow the study protocol\n* Regular medication with benzodiazepine","70 Years",{"count":367,"type":22},60,[79],"Cardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced posttraumatic stress disorder (PTSD) reduces PTSD symptoms and thereby may offset the risk of recurrent or worsening cardiovascular disease. Cardiac-induced PTSD 1) is prevalent, 2) features symptoms unique to internal ongoing somatic threat, with fears and worries that can be distinguished from PTSD resulting from external causes, 3) is persistent, 4) is associated with negative physical and emotional consequences, and 5) has not been the subject of randomized-controlled treatment trials (RCT). There is preliminary evidence suggesting that patients with cardiac-disease induced PTSD might particularly profit from EMDR. Nevertheless, this possibility has not been tested in cardiac-induced PTSD. Currently, patients with cardiac-induced PTSD are not routinely offered trauma-focused therapies, with a lack of scientific evidence likely being one major reason for this omission. If our proposed RCT shows that EMDR can be an effective treatment for patients with ACS-induced PTSD, EMDR could be routinely implemented as first-line treatment. The RCT outcomes might inform larger trials to test whether poor prognosis in terms of major adverse cardiovascular events can be improved through EMDR in patients with cardiac-induced PTSD.",[371,372,373],"Posttraumatic Stress Disorder","Myocardial Infarction","Eye Movement Desensitization and Reprocessing",[375,376,377,378],"PTSD","MI","ACS","EMDR","2026-05-06",{"date":351,"type":36},{"date":382,"type":36},"2020-11-21",{"date":384,"type":22},"2027-11-30",{"name":42,"class":43},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":74,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":44},"100318198","pathophysiology-of-inborn-immunodeficiencies-100318198","NCT03422614","Pathophysiology of Inborn Immunodeficiencies","Pathophysiologie Angeborener Immundefekte","Inclusion Criteria:\n\n* Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID)\n* Clinically healthy (non-age matched) volunteer\n\nExclusion Criteria:\n\n* exclusion of an inborn error of immunity\n* secondary immunodeficiency\n* refusal to enter the study",{"count":315,"type":22},"The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and\u002For a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and\u002For bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.",[396],"Primary Immune Deficiency Disorder","2026-05-05",{"date":379,"type":36},{"date":400,"type":36},"2015-03-01",{"date":402,"type":22},"2033-03-30",{"name":42,"class":43},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":411,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":65},"100292176","phase-2-oral-propranolol-for-prevention-of-threshold-retinopathy-of-prematurity-100292176","NCT03083431","Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity","RoProp","Inclusion criteria:\n\n* Preterm infant born before 28 week's gestation\n* Birth weight below 1250 g\n* At least 5 weeks of age (at randomisation)\n* PMA 310\u002F7 - 36 6\u002F7 weeks\n* Ophthalmoscopic evidence of incipient ROP (stage 1 or 2, with or without plus disease in any zone)\n* Written informed consent by parents or legal guardian, according to national requirements\n\nExclusion Criteria:\n\n* ROP stage ≥ 3, AP-ROP or suspected AP-ROP, or any other ROP requiring an intervention (study endpoint already reached).\n* Conditions that indicate open label propranolol such as: thyrotoxicosis, arterial hypertension or certain heart diseases (such as tetralogy of Fallot, paroxysmal supraventricular tachycardia, or long QT syndrome) etc.\n* Major congenital malformations or known chromosomal anomalies\n* Colobomas and other eye malformations\n* PHACE syndrome (posterior fossa anomalies, large infantile hemangiomas of the face, neck, and\u002For scalp, arterial lesions, cardiac abnormalities\u002Fcoarctation of the aorta, eye anomalies) (risk of cerebrovascular complications)\n* Very large hemangioma (risk of hyperkalemia), as judged by the attending physician\n* Medication of the infant with rifampicin or phenobarbitone (enhanced metabolic clearance)\n* Chronic kidney impairment (serum creatinine \\> 1.3 mg\u002Fdl \\[115 μmol\u002FL\\])\n* Severe liver dysfunction (ALT (GPT) \\> 900 U\u002FL)\n* Known hypersensitivity to propranolol or any of the excipients (see 6.3.1.)\n* Prinzmetal's angina, Raynaud's phenomenon (severe peripheral arterial circulatory disturbance), or pheochromocytoma (contraindications for propranolol in adults, not occurring in newborn infants)\n* Any circumstances that make the investigator believe that participation in the study leads to exceptional medical or organizational problems for the patient\n* Conditions that prohibit propranolol therapy such as: Atrio-ventricular block grade 2 or 3 hypertrophic cardiomyopathy, sinoatrial block, uncontrolled heart failure or cardiogenic shock, bronchial asthma\n* Medication of the infant or the mother if breastfeeding with clonidine, reserpine, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists (contraindicated in preterm infants) or antiarrhythmic drugs including amiodarone, propafenone, lidocaine, digoxin\u002Fdigitoxin, quinidine, verapamil, diltiazem, bepridil (pharmacodynamic interaction)","5 Weeks","15 Weeks",{"count":414,"type":22},276,[25],"Extremely premature infants are at risk of developing a potentially blinding eye disease, called retinopathy of prematurity (ROP). Currently available treatment, consisting of laser surgery or injection of drugs into the eye balls, may prevent most but not all cases of permanent ROP-mediated blindness. Both types of treatment are associated with significant costs and side effects.\n\nAn orally administered drug commonly used to treat hypertension, propranolol, may be effective in halting progression of ROP to severe stages, as suggested by preliminary data from small studies. As severe (threshold) ROP is an overall rare disease, the effectiveness of propranolol in combating ROP can only be assessed in a large, multicenter randomized controlled trial involving hospitals caring for extremely preterm infants of diverse origin.",[418],"Retinopathy of Prematurity","2026-05-04",{"date":351,"type":36},{"date":422,"type":36},"2022-09-22",{"date":356,"type":22},{"name":42,"class":43},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":44},"100557171","stop-stroke-stroke-outcome-prediction-in-the-acute-treatment-setting-100557171","NCT06534645","STOP-stroke: STroke Outcome Prediction in the Acute Treatment Setting","STOP-stroke: STroke Outcome Prediction in the Acute Treatment Setting - a Prospective, Single-center, Observational Study","STOP-STroke","Inclusion Criteria:\n\n* Patients from up to 18 years years of age without any upper age limit.\n* Patients with clinical suspicion of acute ischemic stroke (acute onset focal neurological deficit) at the discretion of the paramedic or treating physician within 24 hours of symptom onset including wake-up situation and unclear symptom onset planned for clinically indicated neuroimaging.\n* Patients with externally performed neuroimaging before admission or referral to the USZ will be included from the time point N2 on if no refusal of use of data is documented.\n\nExclusion Criteria:\n\n• Patients with documented objection of subsequent use of personal health data or patients who reject the use of personal health data during follow-up after initial informed consent by an independent physician in the acute setting. We will not include patients in the study if there is no written informed consent either from the patient her-\u002Fhimself, the next of kin or the independent physician.",{"count":434,"type":22},250,"The STOP-stroke project aims at improving prediction of outcome early after stroke. In order to achieve this, we need to understand reasons (important variables) for prediction in a real clinical prognostication process.\n\nWe aim to:\n\n1. Test the predictive performance of stroke neurologists for outcome prediction (NIHSS at 24 hours and 3 months and mRS at 3 months after stroke onset) prospectively and in a real clinical setting, and to explore the most important baseline variables in their prognostication process.\n2. Test the prediction performance of our DL models when being provided with structured clinical and\u002For imaging information from the same patients as the neurologists; and to discover most relevant features of the input data.\n3. Use the information gained from our experiments for improving our DL algorithm. This will include an error analysis on the missclassifications of models and neurologists to understand the pitfalls of both approaches. We anticipate to develop a robust, reliable and clinically feasible application ready for testing in a prospective, observational trial.",[437],"Stroke Outcome Prediction Supported by Deep Learning Algorithm",[439,440,441],"stroke outcome prediction","deep learning","AI in stroke","2026-05-03",{"date":351,"type":36},{"date":445,"type":36},"2024-10-29",{"date":447,"type":22},"2027-07-30",{"name":42,"class":43},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":466,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":44},"100636653","tubsis-20---tobacco-use-behavioral-support-and-intervention-system-100636653","NCT07568483","TUBSIS 2.0 - Tobacco Use Behavioral Support and Intervention System","Effectiveness of an Internet-based, Self-help, Asynchronized Behavioral Therapy With Mindfulness Approach for Adults With Tobacco Smoking or Vaping to Support Adults in Reducing Tobacco Smoking and Vaping in Switzerland and Türkiye","TUBSIS_2_0","Inclusion Criteria:\n\n* Age: 18 years or older\n* Smoking status:\n\nSmoked on ≥1 day in the past 30 days, and\u002For Smoked at least 100 cigarettes in lifetime\n\n* Internet access: Stable internet connection and access to a smartphone, tablet, or computer during interaction of the TUBSIS 2.0 web-based platform.\n* Language: Sufficient reading and listening comprehension in the study language (German, English or Turkish)\n* Contact: Valid email address and phone number (optional) for study communication, reminders and incentive payments\n* Consent: Provided electronic informed consent on TUBSIS 2.0 web-based platform which is developed and administrated by ISGF.\n* Study procedures: Agreement to randomization (intervention or control) and completion of study assessments at four time points (baseline, mid-intervention, post-intervention and 8-week follow-up)\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria are excluded.",{"count":458,"type":22},406,[79],"Background:\n\nTobacco smoking and vaping remains public health concern, with many adults continuing to experience difficulties accessing appropriate support for smoking cessation in Switzerland and Türkiye. Structural barriers, including stigma related to attempting to quit, limited financial and time resources, low awareness of the health risks associated with tobacco smoking- and vaping-reduce engagement with traditional services. TUBSIS 2.0 aims to address these access inequities by providing a fully remote, anonymous and free internet-based program tailored to diverse adult populations in both countries.\n\nObjectives:\n\nThe \"TUBSIS 2.0: An Adaptation Study of Tobacco Addiction Support Programme - TUBSIS for Tobacco Users in Switzerland and Türkiye\" project aims to support readiness to reduce or quit tobacco smoking\u002Fvaping, improve well-being and self-compassion and strengthen health-related behaviors. The intervention targets German-, English-, and Turkish-speaking adults and includes mindfulness-based strategies for quitting or reducing tobacco smoking and vaping. Motivation to cease tobacco smoking\u002Fvaping varies considerably across the lifespan. Younger individuals may perceive smoking\u002Fvaping cessation as unnecessary, often due to limited awareness of long-term health risks or a sense of invulnerability. In later adulthood, although addiction tends to be more deeply established, many individuals hesitate to attempt cessation because of concerns about the psychological and behavioral challenges associated with the process. It is therefore essential to provide individuals with support that helps them understand the cessation process, prepare for the challenges that can be expected and identify strategies that align with their psychological needs. Such strategies may include stress management and self-compassion practices that can be utilized before, during and after cessation attempts. TUBSIS 2.0 offers structured and accessible guidance to support this preparation by providing a clear, evidence-based pathway for individuals at different stages of readiness to change.\n\nMethods:\n\nTUBSIS 2.0 is a web-based, individual and asynchronous program consisting of eight modules delivered over four weeks. A total of 406 participants will be recruited and randomly assigned to either the intervention or control group. Data are collected anonymously at four measurement points (baseline, mid-term, post-term and 8-week follow-up) from participants. The program focuses on supporting participants' reducing or quitting tobacco smoking or vaping; to increase their readiness for smoking\u002Fvaping cessation, mental well-being, self-compassion and stress management with mindfulness strategies.\n\nWithin the Health Action Process Approach (HAPA), the process of behaviour change is conceptualised as a dynamic, non-linear process that progresses through motivational and volitional phases. TUBSIS 2.0 has been adapted to reflect this structure by integrating phase-specific components. These components include modules that enhance risk awareness and outcome expectancies, planning and self-regulation tools to support action initiation and mindfulness-based strategies that are embedded throughout all phases to strengthen self-efficacy and coping. By addressing these shifting needs across the change process, the programme provides a responsive and theory-driven pathway for reducing\u002Fquitting tobacco smoking or vaping.\n\nRelevance:\n\nTUBSIS 2.0 is highly relevant to public health priorities, as it provides a cost-effective, scalable and environmentally sustainable intervention that eliminates barriers commonly associated with traditional cessation services. By requiring no travel, printed materials or in-person appointments, the programme offers equitable access to adults across all age groups, genders and diverse migrant communities in Switzerland and Türkiye. Its multilingual and culturally adapted structure addresses significant service gaps for populations that are underserved or hesitant to seek conventional support. By reducing tobacco smoking- or vaping-related harm and facilitating early behavioural change, TUBSIS 2.0 has the potential to decrease long-term healthcare costs while expanding access to evidence-based digital prevention tools.",[462,463,464,465],"Tobacco Use Disorder","Nicotine Dependence","Vaping","Smoking Tobacco",[467,468,469,470,471],"smoking tobacco","vaping","web-based intervention","mindfulness","Health Action Process Approach","2026-04-30",{"date":397,"type":36},{"date":475,"type":36},"2025-11-15",{"date":477,"type":22},"2026-08-31",{"name":42,"class":43},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":365,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":492,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":44},"100629196","activating-social-resources-in-psychotherapy-seeking-individuals-effectiveness-and-timing-of-a-social-support-just-in-time-adaptive-intervention-100629196","NCT07471529","Activating Social Resources in Psychotherapy-Seeking Individuals: Effectiveness and Timing of a Social Support Just-in-Time Adaptive Intervention","Inclusion Criteria:\n\n* indicating to seek outpatient psychotherapy\n* elevated levels of self-reported depressive symptoms (Beck Depression Inventory-II (BDI) score \\> 13 (out of 63); Kühner et al., 2007)\n* owning a smartphone\n* signing the informed consent form\n\nExclusion Criteria:\n\n* first session for outpatient psychotherapy is scheduled within four weeks\n* suicidal ideation (values \\> 2 in BDI item 9)\n* presence of manic symptoms (Mood Disorder Questionnaire (MDQ) score \\> 7), - shift work\n* age below 18 or above 70",{"count":77,"type":22},[79],"This study evaluates a Just-In-Time Adaptive Intervention (JITAI) aiming to foster social support processes for adults with elevated depressive symptoms awaiting outpatient psychotherapy. Utilizing a daily-level micro-randomized trial (MRT) design conducted over 21 days, participants are assessed six times daily. Participants are randomized across four conditions: (1) vulnerability-triggered, (2) vulnerability and receptivity-triggered, (3) support-need-triggered, and (4) a no-intervention control. The primary objective of this study is to evaluate the effectiveness of the JITAI in reducing daily depressive symptoms and increasing received social support (primary outcomes), as well as reducing daily loneliness and enhancing perceived social support (secondary outcomes). Furthermore, the study aims to compare the relative efficacy of three distinct triggering strategies to identify the most effective timing for intervention delivery.",[489,490,491],"Loneliness","Social Support","Depressive Symptoms",[490,489,493,494,495,491],"Just-in-Time Adaptive Intervention","JITAI","Ecological Momentary Intervention","2026-04-29",{"date":472,"type":36},{"date":499,"type":36},"2026-04-22",{"date":501,"type":22},"2026-12",{"name":42,"class":43},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":522,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":530,"leadSponsor":532,"locationsCount":65},"100577927","phase-2-pharmacoscopy-for-patients-with-refractory-primary-brain-tumors-100577927","NCT06804655","Pharmacoscopy for Patients With Refractory Primary Brain Tumors","EViDENCE-BT","Inclusion Criteria:\n\n1. Age 18 years or older on day of signing informed consent, female or male.\n2. Refractory glioblastoma, isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma, histone-mutant glioma, ependymoma, medulloblastoma, meningioma or other rare primary brain tumor with a histological confirmation according to the WHO classification 2021. Primary tumors can be located at the cerebral or spinal level. Primary brain tumors with metastases outside of the brain may also be considered.\n3. Karnofsky performance status of 60 or more\n4. Life expectancy \\>12 weeks.\n5. Limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.\n6. Surgery clinically indicated. A histological confirmation of the diagnosis of a recurrent brain tumor will be required before any treatment can be initiated.\n7. Adequate bone marrow, renal and hepatic function\n8. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.\n9. Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.\n\nExclusion Criteria:\n\n1. Inability to undergo brain or spine MRI.\n2. Concurrent treatment with other systemic tumor-directed pharmacotherapies.\n3. Intent to be treated with radiotherapy.\n4. Any investigational antitumor therapy other than those under investigation in this study.\n5. Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions and requirements.\n6. Intention to become pregnant during the course of the study or pregnancy. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test.\n7. Women who are breast feeding and who do not agree to discontinue nursing prior to the first study treatment and for the period defined in the protocol.\n8. Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.",{"count":511,"type":22},40,[25],"Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment.\n\nThe study is supported by an unrestricted grant from Anti Cancer Fund.",[515,28,516,517,518,519,520,521],"Brain (Nervous System) Cancers","Glioma","Ependymoma","Medulloblastoma","Meningioma","Rare Primary Brain Tumors","Rare CNS Primary Tumors",[523,524,525,526,527],"pharmacoscopy","drug testing","refractory tumor","drug repurposing","personalized medicine",{"date":379,"type":36},{"date":182,"type":22},{"date":531,"type":22},"2028-09-15",{"name":42,"class":43},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":23,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":551,"leadSponsor":553,"locationsCount":4},"100612307","supercable-vs-conventional-steel-wire-for-closure-after-a-median-sternotomy-100612307","NCT07251881","SuperCable vs. Conventional Steel Wire for Closure After a Median Sternotomy","Prospective-randomized Trial to Demonstrate Superiority of SuperCable vs. Conventional Steel Wire for Closure After a Median Sternotomy","SURE","Inclusion Criteria:\n\n* Provision of Informed Consent: The subject must have signed and dated the informed consent form prior to any study-related procedures.\n* Willingness and Ability to Comply: The subject must express a stated willingness to comply with all study procedures and be available for the duration of the study.\n* Age and Sex:\n\n  * Age: The subject must be at least 18 years old.\n  * Sex: Both male and female subjects are eligible. In line with the \"Sex and Gender in Research Involving Humans\" recommendations, data will be stratified and analyzed by sex to identify any potential differences in outcomes.\n* Language Competence: The subject must possess sufficient German language skills to accurately complete the postoperative survey\n* Travel Capability: The subject must have the ability to travel for all planned study visits, including scheduled CT scans\n* Surgical Procedure: The subject must be scheduled for elective coronary artery bypass graft (CABG) procedures, as this is the focus of the investigation\n* Adherence to Visit Schedule: The subject must be willing to adhere to all scheduled visits and undergo CT scans as outlined in the study protocol\n\nExclusion Criteria:\n\n* Pharmacological Restrictions: Current use of corticosteroids or any immunosuppressive medication\n* Prior Treatments and Therapies: History of radiation therapy to the thorax\n* Reproductive Considerations:\n\n  * Pregnancy, or the intent to become pregnant during the study period\n  * Lactation or current breastfeeding\n* Allergic Reactions: Known allergic reactions to components of the conventional steel wire or SuperCable, specifically any known metal allergies (e.g., nickel or titanium).\n\nExample: Patients with a documented history of nickel allergy, including previous adverse reactions to products such as sternal cerclages, will be excluded\n\n* Infectious or Febrile Conditions: Any febrile illness occurring immediately before the scheduled surgery\n* Concurrent Investigational Treatments: Treatment with another investigational drug or medical device within two months preceding surgery, as well as during the current investigation\n* Surgical History: Subjects who have undergone prior sternotomy and osteosynthesis (i.e., re-do patients) will be excluded\n* Anatomical Considerations:\n\n  * Known sternal deformities that could compromise the outcome of the investigation\n  * Off-midline sternotomy approaches, as these do not align with the surgical technique under investigation\n* Patient Residence and Follow-Up Feasibility: Subjects residing in remote regions, including those from interstate or overseas, where follow-up and adherence to the scheduled visits might be compromised\n* Other Specific Exclusions: Any additional criteria specific to the disease under investigation or identified by the investigator based on medical judgment (e.g., clinically significant concomitant disease states such as renal failure, hepatic dysfunction, or cardiovascular disease, if these conditions are deemed to interfere with study outcomes)",{"count":542,"type":22},86,[79],"During certain heart surgeries, the sternum is opened and must then be closed securely. The study compares two closure methods - steel wires and SuperCable - in terms of stability, healing, and patient satisfaction. This investigation aims to demonstrate that the iso-elastic properties of the SuperCable Sternal Closure System result in faster sternal bone healing, reduced postoperative pain, shorter hospital stay, and improved physical recovery compared to conventional steel wire sternal closure. Eighty-six patients are participating and are randomly assigned to one of the two groups. After the operation, pain, healing, and possible complications are checked. The patients are examined 3 and 6 months after the operation.",[546],"Sternotomy","2026-04-28",{"date":549,"type":36},"2026-05-01",{"date":303,"type":22},{"date":552,"type":22},"2027-07",{"name":42,"class":43},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":23,"phases":563,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":583,"leadSponsor":584,"locationsCount":44},"100626921","auditory-sleep-stimulation-or-sham-in-people-with-parkinson-disease-mild-cognitive-impairment-during-cognitive-training-100626921","NCT07441915","Auditory Sleep Stimulation or Sham in People With Parkinson Disease Mild Cognitive Impairment During Cognitive Training","Non-pharmacological Enhancement of Deep Sleep With Auditory Stimulation Versus Sham in People With Parkinson's Disease and Mild Cognitive Impairment Receiving Cognitive Training: A Double-blind Randomized Trial (PD-CogT-Sleep)","PDCogTSleep","Inclusion Criteria:\n\n* clinical diagnosis of PD along the MDS criteria (Postuma et al., 2015)\n* MCI according to the MDS criteria, level I (Litvan et al., 2012):\n* \\- cognitive decline: Gradual decline, in the context of established PD, in cognitive ability reported by either the patient or informant, or observed by the clinician, AND\n* \\- MoCA ≤ 26 and ≥ 18 (Hoops et al., 2009)\n* stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study\n* ability to apply the sleep intervention for the duration of study, either alone or with assistance of a co-habitant if needed\n* ability to apply the CogT intervention for the duration of study\n* sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes\n* dosing of dopaminergic and other PD treatment must have been stable for at least 14 days prior to the intervention period and will be expected to remain stable until the end of the study.\n\nExclusion Criteria:\n\nDiagnosis\u002FComorbidities:\n\n* clinical diagnosis of dementia (cognitive impairment sufficient to interfere with independence in everyday activities, i.e. \"major neurocognitive disorder\", DSM-5)\n* known presence of neurologic (other than PD) or psychiatric disorder\n* Parkinsonism without response to levodopa; atypical Parkinsonian syndromes as assessed from medical history and clinical examination\n* severe medical conditions (for example, renal insufficiency, liver failure, or congestive heart failure) as assessed in the semi-structured screening interview\n* regular use of benzodiazepines and other central nervous system (CNS)-depressant substances as assessed in the semi-structured screening interview\n* known or suspected drug- or medication abuse as assessed in the semi-structured screening interview\n* substance or alcohol abuse (i.e. \\> 0.5 l wine or 1 l beer per day) as assessed in the semi-structured screening interview\n\nSleep disorders that could interfere with the sleep intervention:\n\n* obstructive sleep apnea with apnea-hypopnea index (AHI)\\>15, apnea-related NREM sleep fragmentation, and indication for treatment (in turn, primarily REM-related sleep apnea, not requiring specific treatment may be considered eligible); or use of continuous positive airway pressure (CPAP)\n* Restless Legs Syndrome\n* frequent (i.e. weekly) Non-REM sleep parasomnia (Sleep disorders typically associated with PD will not lead to exclusion, i.e. REM sleep behavior disorder, insomnia, nocturnal PD symptoms.)\n\nPTAS:\n\n* inability to hear the tones produced by the sleep headband (TOSOO Axora device)\n* non-responder to PTAS during screening (PTAS does not evoke a discernable auditory evoked potential AEP)\n* skin disorders\u002Fproblems\u002Fallergies in face\u002Fear area that could worsen with electrode application\n* known or suspected non-compliance\n\nCognition \\& informed consent:\n\n* inability to follow the procedures of the study, e.g. due to language problems, cognitive deficits\n* failure to give informed consent\n\nOther studies:\n\n* participation in another study with investigational interventions within 30 days (PTAS) or 1 year (CogT) preceding and during the present study\n* previous enrolment in the current study\n* enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n\nSpecial events \u002F behavior with impact on circadian rhythm, sleep, or cognition:\n\n* shift work (work during the night)\n* travelling more than 2 time zones in the last month before intervention starts or during intervention (start of intervention will be adapted to fit with this criteria)\n* planned medical intervention of substantial relevance, e.g. surgery, during intervention (routine assessments, e.g. check-ups will be allowed)\n\nPregnancy:\n\n* women who are pregnant or breastfeeding,\n* intention to become pregnant during the course of the study,\n* lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female participants who are surgically sterilized\u002Fhysterectomized or post-menopausal for longer than 1 year are not considered as being of child bearing potential.",{"count":109,"type":22},[79],"People with Parkinson's disease are at higher risk of cognitive decline, and current treatments cannot fully prevent this. This study explores non-drug ways to support brain function.\n\nIntervention: Participants will complete a 5-week cognitive training program at home (\"brain fitness\"). In addition, they will use a sleep device at night that plays soft sounds to improve deep sleep; Half of the participants will actually receive these sounds (auditory stimulation), while the other half will receive a sham (placebo) version - neither the participants nor the researchers will know the group assignment.\n\nAssessments will take place before and after the intervention, and again three months later, including one overnight stay at University Hospital Zurich per assessment.\n\nThe goal is to find out whether improving deep sleep can boost the benefits of cognitive training and help slow cognitive decline in Parkinson's disease.",[566,567],"Parkinson's Disease","Mild Cognitive Impairment",[569,570,566,571,567,572,573,574,575,576,577,578,579],"PD-MCI","Sleep","Neurodegeneration","Cognitive Training","Digital Cognitive Training","Auditory Stimulation","Acoustic Stimulation","Randomized Clinical Trial","Wearable Device","Electroencephalography","Blood-based Biomarkers","2026-04-24",{"date":472,"type":36},{"date":499,"type":36},{"date":256,"type":22},{"name":42,"class":43},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":18,"minAge":592,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":601,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":44},"100575764","boosting-refugee-integration-through-psychological-intervention-100575764","NCT06776523","Boosting Refugee Integration Through Psychological Intervention","BRIGHT","The inclusion criteria for participating in the study are:\n\n* refugees and asylum seekers (RAS) aged 16 or older;\n* residing in one of the participating local sites (Swiss municipalities, namely, Gemeinden, and transitional asylum centers, namely, Durchgangszentren) where PM+ is offered and which gave their consent for participation in the RCT;\n* speaking at least one of the following 12 languages: German, English, French, Arabic, Farsi, Kurdish, Tigrinya, Turkish, Ukrainian, Russian, Tamil, and Pashto;\n* obtaining a score of 20 or higher on the Kessler Psychological Distress Scale (K10; Kessler et al., 2002), a brief clinically validated screening questionnaire that assesses general psychological distress in the past 30 days. A score equal to or higher than 20 is used as an indication of moderate to high levels of psychological distress.\n\nThe exclusion criteria for participating in the study are:\n\n* significant cognitive or neurological impairment measured through specific tools developed by the WHO and integrated into the PM+ manual (impairment questionnaire);\n* acute medical conditions or severe mental disorders (e.g., psychotic or substance-abuse disorders) measured through specific tools developed by the WHO and integrated into the PM+ manual (impairment questionnaire);\n* acute risk of suicide as measured by the Suicidal Ideation Attribution Scale (SIDAS; van Spijker et al., 2014) and the Thoughts of Suicide Questionnaire (World Health Organization WHO, 2016).","16 Years",{"count":594,"type":22},1200,[79],"Refugees and asylum seekers (RAS) face numerous stressors and adversities which put them at risk for developing mental health problems. However, access to adequate mental health care in host countries is limited. To address this problem, the World Health Organization (WHO) introduced Problem Management Plus (PM+), a short, low-intensity psychological intervention administered by non-professionals, aiming to alleviate common mental disorders among crisis-affected communities.\n\nThe present study aims at expanding the existing PM+ intervention by providing additional booster sessions and homework reminders while evaluating its effectiveness and implementation in the public health system.",[598,375,599,600],"Psychological Distress","Trauma","Common Mental Health Problems",[602,598,603,604],"Problem Management Plus","Mental Health Care","Refugees","2026-04-21",{"date":607,"type":36},"2026-04-27",{"date":609,"type":36},"2025-01-16",{"date":611,"type":22},"2027-09",{"name":42,"class":43},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":622,"conditions":623,"keywords":628,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":44},"100634025","investigation-of-brain-blood-flow-changes-in-acute-ischemic-stroke-patients-after-successful-endovascular-thrombectomy-100634025","NCT07534319","Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy","RESTORE-AIS","Inclusion Criteria:\n\n* Male and female subjects \\>18 years old.\n* Acute ischemic stroke related to a new occlusion of the internal carotid artery, middle cerebral artery (M1- and\u002For M2-segment), or both.\n* Eligibility and performance of endovascular thrombectomy.\n* Achievement of successful recanalization, defined as mTICI score ≥2b\n* Written informed consent of the patient or when the patient is not able to participate in the consenting procedure, the written authorization of a family member. Foreign speaking patients should be included by a person with sufficient German language proficiency to act as a translator.\n\nExclusion Criteria:\n\n* Documented evidence or a confirmed willingness of the patient not to participate in any scientific study.\n* Standard contraindications for MRI, such as pacemaker, metallic prothesis, glaucoma, metallic tattoo dyes, verbal confirmed pregnancy. Unwilling or unable to cooperate with breathing manoeuvres.\n* Major cardiopulmonary diseases, such as severe uncontrolled asthma bronchiale, severe chronic obstructive lung disease (i.e., GOLD stage ≥III), diffuse interstitial lung disease, pulmonary embolism, acute\u002Fsubacute myocardial infarction, or severe heart failure (i.e., NYHA class ≥III).\n* Symptomatic increased intracranial pressure.\n* Presence of intracranial haemorrhage type ≥2 according to the Heidelberg classification.\n* New onset of seizure.",{"count":621,"type":22},100,"Introduction:\n\nEndovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion. However, in clinical practice, nearly half of the patients do not experience adequate neurological improvement despite successful recanalization - a phenomenon termed reperfusion failure or clinically ineffective reperfusion. Given the clinical relevance of this phenomenon and the absence of a standardized imaging diagnostic method to identify it, our project aims to explore the potential role of blood oxygenation-level dependent cerebrovascular reactivity (BOLD-CVR) as novel imaging biomarker for studying reperfusion failure.\n\nStudy population:\n\nAdult patients with acute ischemic stroke of the ICA, MCA or with tandem occlusion who have undergone a successful recanalization, described as mTICI score ≥2b.\n\nObjective(s):\n\nPrimary objective: to longitudinally observe blood flow changes derived from BOLD-CVR imaging following successful endovascular thrombectomy in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS) during the early post-treatment phase and assess their association with clinical outcome 90 days post-EVT.\n\nSecondary objective: to compare BOLD-CVR findings with those obtained from the clinical standard dynamic susceptibility contrast (DSC) MR perfusion imaging acquired in the same examination session as well as other imaging techniques included in the standard post-treatment imaging protocol at our institution.\n\nOutcomes:\n\nClinical outcomes:\n\n* 90-day functional outcome.\n* Functional outcome at hospital discharge.\n* Neurological deterioration during hospitalization.\n* Radiologically confirmed haemorrhagic transformation within the reperfused tissue.\n* Radiologically confirmed infarct lesion progression within the reperfused tissue.\n* Additionally, DSC MR perfusion imaging parameters and other standard hemodynamic imaging parameters will be considered as imaging outcomes\n\nStudy design:\n\nSingle-center prospective observational cohort study\n\nMeasurements and procedures:\n\nIncluded patients will undergo a total of 3 BOLD-CVR examinations: 72 hours, 7 days, and 90 days after EVT. Participation in the final examination will mark the end of the subject's involvement in the study. Clinical outcomes will be prospectively collected as per established institutional patient management protocols: during hospitalization, at discharge, and at the cerebrovascular outpatient clinic at 3 months.\n\nNumber of Participants:\n\nTarget sample size: 100 patients\n\nGiven the observational study design and exploratory nature of this project, no sample size calculation can be performed. The provided target sample size (N = 100) has been estimated considering the inclusion of as many consecutive subjects as possible.\n\nStudy period: 2.5 years The investigators aim to enroll a target sample size of 100 patients over a period of 2.5 years. This translates to an inclusion of 3-4 patients per month, with the last three months allocated for the follow-up of the last included patients.\n\nStudy Centre:\n\nClinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich\n\nStatistical Considerations:\n\nThe association between BOLD-CVR findings and clinical outcomes will be investigated using regression analyses.",[624,625,626,627],"Acute Cerebrovascular Accident","Thrombectomy","Cerebral Revascularization","No Reflow Phenomenon",[629,625,630,626,627,631,632],"Acute Ischemic Stroke","Reperfusion Failure","BOLD-CVR","Advanced Haemodynamic Imaging","2026-04-09",{"date":635,"type":36},"2026-04-16",{"date":637,"type":36},"2025-06-01",{"date":639,"type":22},"2027-12-01",{"name":42,"class":43},{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":647,"eligibilityCriteria":648,"healthyVolunteers":74,"sex":18,"minAge":592,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":651,"conditions":652,"keywords":658,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":4},"100632686","evaluation-of-free-sti-testing-pilot-projects-in-lucerne-and-zurich-switzerland-100632686","NCT07516912","Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland","feSTI: Evaluation of Free HIV and STI Testing and Counselling Services for Young and Disadvantaged Populations in Lucerne and Zurich","feSTI","Inclusion Criteria:\n\n* taking part in the pilot programmes\n* understand the study information\n* 16 years of age or older\n\nExclusion Criteria:\n\n* not eligible for the pilot programmes\n* not understanding the study information\n* less than 16 years old",{"count":650,"type":22},1800,"The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.",[653,654,655,656,657],"HIV (Human Immunodeficiency Virus)","Chlamydia","Gonorrhea","Syphilis","HCV",[659,660,661,662,663],"Voluntary counselling and testing","sexually transmitted infections","HIV","implementation of free testing","barriers to care","2026-04-02",{"date":666,"type":36},"2026-04-08",{"date":668,"type":22},"2026-04-07",{"date":670,"type":22},"2029-02-28",{"name":42,"class":43},""]